Brief: Gracell Biotechnologies To Present Updated Results Of Therapy For Relapsed/Refractory Multiple Myeloma At ASCO
19/05/2021 22:39
May 19 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES TO PRESENT UPDATED RESULTS OF
GC012F
FASTCAR-ENABLED BCMA/CD19 DUAL-TARGETING CAR-T CELL THERAPY FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA AT ASCO 2021 AND EHA 2021
Source text for Eikon: ID:nPnbqKXW8a
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27